- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Segment 3: The Trouble with Prognostic Tests
Payers differentiate between predictive and prognostic diagnostic tests, and one is definitely more useful than the other, according to John L. Fox, MD, MHA, of Priority Health, and Bryan Loy, MD, MBA, of Humana.
Payers differentiate between predictive and prognostic diagnostic tests, and one is definitely more useful than the other, according to John L. Fox, MD, MHA, of Priority Health, and Bryan Loy, MD, MBA, of Humana.
In the predictive space, payers are looking to see if a specific biomarker can be used to predict whether or not a drug will produce better outcomes in certain patient populations, and there is good evidence of clinical utility, according to Dr Fox.
He and Dr Loy agree, though, that having the evidence of an association between a test and an outcome isn’t enough because whether or not the information is being used correctly is often unstudied.
“Having the study doesn’t necessarily mean that we’re going to get the value out of those tests as a payer,” Dr Loy said. “Having a good test in the wrong hands or if the information never gets utilized, there is not value for us.”
Personalized Care Key as Tirzepatide Use Expands Rapidly
April 15th 2025Using commercial insurance claims data and the US launch of tirzepatide as their dividing point, John Ostrominski, MD, Harvard Medical School, and his team studied trends in the use of both glucose-lowering and weight-lowering medications, comparing outcomes between adults with and without type 2 diabetes.
Listen
Drug Interactions With Ibrutinib Common, Linked to Higher Infection Risk in CLL
September 16th 2025Drug interactions with ibrutinib may not shorten survival when managed carefully, though the significant increase in infection-related hospitalizations tied to CYP3A inhibitors signals an urgent need for closer monitoring, dose adjustment, and proactive infection prevention strategies.
Read More
